In May last year, Japan-based drugs company Takeda Pharmaceutical's corporate venturing unit made an equity investment of undisclosed size in Fate Therapeutics as part of a plan to help its parent move into regenerative medicines.
Fate Therapeutics, a US-based drugs company, has raised $9.2m from 17 investors, according to a regulatory filing first seen by news provider Fierce Biotech.
In May last year, Japan-based drugs company Takeda Pharmaceutical’s corporate venturing unit made an equity investment of undisclosed size in Fate Therapeutics as part of a plan to help its parent move into regenerative medicines.
Takeda Ventures joined peers Astellas Venture Management, Genzyme Ventures and a third, unnamed corporate venturing group as strategic investor in…
